Atria Investments Inc Boosts Stake in Global X Genomics & Biotechnology ETF $GNOM

Atria Investments Inc raised its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 12.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,520 shares of the company’s stock after buying an additional 2,073 shares during the quarter. Atria Investments Inc owned about 0.37% of Global X Genomics & Biotechnology ETF worth $156,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GNOM. Flow Traders U.S. LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 10.0% during the first quarter. Flow Traders U.S. LLC now owns 156,662 shares of the company’s stock valued at $1,245,000 after acquiring an additional 14,280 shares during the last quarter. Jane Street Group LLC raised its stake in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after purchasing an additional 10,308 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Global X Genomics & Biotechnology ETF by 8.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock valued at $756,000 after purchasing an additional 6,708 shares in the last quarter. Insight Advisors LLC PA boosted its stake in shares of Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after purchasing an additional 19,319 shares during the last quarter. Finally, Manhattan West Asset Management LLC grew its holdings in shares of Global X Genomics & Biotechnology ETF by 13.0% during the first quarter. Manhattan West Asset Management LLC now owns 29,947 shares of the company’s stock worth $238,000 after buying an additional 3,439 shares in the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Price Performance

NASDAQ:GNOM opened at $43.13 on Friday. The firm has a market cap of $52.62 million, a PE ratio of -18.43 and a beta of 1.22. The firm has a 50 day simple moving average of $40.98 and a 200-day simple moving average of $36.42. Global X Genomics & Biotechnology ETF has a 1-year low of $27.20 and a 1-year high of $45.47.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.